Medical Devices Regenerative medicine Technology Search | ipal – Ihr professioneller Vermarkter von Erfindungen / Patenten

Intravenous Catheter: A New IV Catheter Device Featuring Automatic and Integrated Blood Sampling

05.01.2010 | Ref.Nr. 04091

Life Science › Medical Devices › Regenerative medicine

We offer a new IV catheter for the use during emergency and disasters to automatically preserve a pre-infusion bloodsample from every patient. The new catheter system is based on existing IV devices. Its new features include an integrated blood sampling reservoir that is fixed to the IV catheter via a flexible plastic band and remains attached to the patient following self-filling with a small blood volume until admission in the hospital. Upon arrival, the reservoir is labeled with the patient ID, disconnected from the patient and immediately sent to the laboratory for blood group typing.

Thus, the device ensures rapid and precise ABO typing in 100% of emergency patients. Furthermore, it increases patient safety by securing this precious very first blood sample in every case in addition to the sample taken from a central line inserted inside the hospital. Thereby two independently drawn specimens are available for ABO-typing even in circumstances with extreme time constraints.

IP Rights
Patent pending in the US, EP, and DE

Origin
The catheter system was developed at the Charité – Universitätsmedizin Berlin.

Application Area:

Emergency Medicine, Medical Technology, Military

Development Stage: Clinical tests

Type of Collaboration: License

Schlagworte: Blood, Catheter, Laboratory, Patient, Sampling,

Weitere Kategorien: Life Science, Medical Devices, Regenerative medicine

Licensing Manager: Marcel Tilmann

T +49 30 2125 4827

F +49 30 2125 4822

marcel.tilmann@ipal.de

Market Potential: Worldwide

Benefits:

Secure blood transfusions
Increased patient security
Catheter and reservoir are both labeled with the patient ID to avoid false blood infusions
Rapid and precise ABO typing

A bone cement composition for the creation of a MRT-signaling bone cement

14.09.2009 | Ref.Nr. 07147

Download as PDF PDF Download Share

Life Science › Medical Devices › Regenerative medicine

Bone cements based on polymethylmethacrylate (PMMA) are mostly used for the anchorage of artificial joints, as bone substitutes at backbone diseases or after tumour surgeries, for the encouragement of implants (e.g. plates, nails) or as placeholder in infected joints. Most bone cements are produced by the combination of a 2-phase-system, containing a powder (PMMA) and a fluid (MMA).

Especially during the insertion of bone cement into fractured vertebral bodies or cleared tumour caves (vertebroplasty) it is necessary to follow the operation process by MR imaging to ensure the right position of the bone cement (“open MRI”). Therefore the researchers developed bone cement with paramagnetic properties to induce a MRT detectable signal. They added sodium chloride solution containing a contrast agent to the MMA and proceeded as done by common bone cement production. In this way they achieved modified bone cement that can induce a MR signal by keeping all conventional properties.

IP Rights
A PCT application was filed on February 2nd, 2009 (priority on February 2nd, 2008)

Origin
The technology was developed at Charité - Universitätsmedizin Berlin.

Application Area:

Pharma & Medical

Development Stage: Proof of Concept

Type of Collaboration: License

Schlagworte: Bone Cement, MRT, PMMA,

Weitere Kategorien: Life Science, Medical Devices, Regenerative medicine

Licensing Manager: Dr. Janin Hofmann

T +49 30 2125 4828

F +49 30 2125 4822

janin.hofmann@ipal.de

Market Potential: Worldwide

Benefits:

Low technical risk
Growing market for implants
MRT-controlled surgeries are possible
Overcomes the disadvantage of common bone cement not to generate a signal detectable by MR imaging

Combined Application of an Agent Carrying a Target-Cell Specific Ligand and a Saponin

16.02.2009 | Ref.Nr. 04047

Download as PDF PDF Download Share

Life Science › Medical Devices › Regenerative medicine

We offer a novel approach for a high uptake of a pharmacologically active agent and an enhanced specificity towards its target. One of the most significant problems in tumor therapy is the incomplete removal of tumors by local treatment, since a complete and lasting tumor remission by chemotherapy or radiation therapy works only for a few tumor entities.

Therefore, a promising approach to solve this problem is an immunological therapy by which a pharmacologically active agent is applied to a patient with preferable high tumorspecificity. However, quite frequently, one is not able to achieve sufficiently large concentrations of the pharmacologically active agent at the intended site of action, either because the agent never reaches the site in the first place or is metabolized too quickly without being able to exert its action. One way of approaching this problem in the past has been to combine the pharmacologically agent with a target specific component so as to increase the likelihood of the agent reaching the target.

IP Rights
EP 04 016 497.2 filed on July 13, 2004, US, JP

Origin
The technology was developed at the Charité - Universitätsmedizin Berlin/Germany.

Application Area:

Pharmaceutical industry

Development Stage: Preclinic

Type of Collaboration: License

Schlagworte: Cellular Targeting, Pharmacological, Saponin, Tumor,

Weitere Kategorien: Life Science, Medical Devices, Regenerative medicine

Licensing Manager: Marcel Tilmann

T +49 30 2125 4827

F +49 30 2125 4822

marcel.tilmann@ipal.de

Market Potential: Worldwide

Benefits:

By combining the application of pharmacologically active agents (such as cytotoxins in the case of tumor therapy, e. g. Ontak™) carrying target-cell specific ligands with a saponin, the uptake of the agent can be enhanced more than ten thousand fold. Due to this specific enhancement, the total concentration of the agent can be reduced by a comparable factor still achieving the desired effects towards e. g. tumor cells. Severe side-effects, however, such as cytotoxicity towards benign cells, are thereby suppressed. Target cell specific ligands can be covalently coupled or non-covalently associated to the pharmacologically active agent or can be expressed as a fusion protein with the agent. Beside the application in tumor therapy, a more general approach can be anticipated regarding any therapy in which difficulties in transferring an agent into a specific
compartment exist (e. g. treatment of inflammatory diseases by cell-specific inhibition of inflammatory mediators).

Automatic Suturing Device for Single Button Sutures

07.11.2008 | Ref.Nr. 06113

Download as PDF PDF Download Share

Life Science › Medical Devices › Regenerative medicine

Suturing during laparoscopic operations is laborious and time-consuming, due to the limited space and 2-dimesional sight. Automating the surgical knot creation can lessen the operation time and can also guarantee a reproducible and controllable knot quality.

The technology offered, provides an automatic suturing device, which can be used to create single button sutures. The automatic suture device allows to make single button sutures with one knot per stitch. It combines the speed of surgical stapling with the reliability and security of single button sutures

IP Rights
German Patent application, DE 102006043114.6 , filed on 8. of September 2006.

Origin
The technology offered, was developed at the Technical University of Berlin.